Open Antibody Sourcing*

We have a good understanding of existing technologies for antibody-drug conjugates, suitable targets and available antibodies. In our Open Antibody Sourcing initiative, we seek to collaborate with you!


 

* This program is not open to U.S. healthcare professionals.

We are looking for antibodies for cancer therapy

We are looking for antibodies against tumour-specific targets in humans. The target should be expressed on the surface of human cancer cells. The epitope recognised by the antibody can be a peptide sequence, a sugar moiety, a lipid, or a mixture of these. The antibody can be monospecific, bispecific or multi-specific. The antibody should show no or little binding to normal healthy human tissue, by being directed against a target that is expressed on tumour cells, but not or to a much lesser extent in normal tissue. This can also include a bispecific approach against two non-tumour specific targets that are co-expressed in tumour tissue, but not in normal tissue.

Theantibody can be at an early stage (i.e. requiring further engineering and optimisation). Ideally, the antibody would be cross-reactive to rodent species to facilitate early safety studies. However, lack of such cross-reactivity is not an exclusion criterion per se. The antibody candidate should have good internalisation properties, or at least have a clear potential to be tailored in this direction.

Who can apply?

We envision proposals from a wide range of academic and non-academic institutions, including start-ups and small and medium-sized enterprises (SMEs). You do not personally need to have experience in antibody drug conjugate technologies, but your proposed antibody should have a good selectivity for the tumour-specific antigen/target. You should also be in the legal position to offer the antibody to us for further clinical use and development.

This program is not open to U.S. healthcare professionals.    

How does it work?

We are only interested in proposals for antibodies that are available for licensing, including full IP rights and exclusive rights for the development and usage of the antibody as an antibody-drug conjugate and for diagnostic purposes.

Your benefits

We will evaluate and assess your proposal in our Research & Development organization. If your proposal is of interest to us, we will get back to you within four weeks to discuss the next steps towards a licensing agreement.

How to apply

Your proposal should contain non-confidential information only. Please include the
following:

1. Collaboration Proposal

a) A description of and proof for the tumour specificity of the antibody/antibodies offered. You can withhold proprietary information if necessary, but should provide enough information for us to be able to appreciate the merits of your approach.

b) A brief discussion of your capabilities and prior experience as relevant to the problem, including any appropriate publications or citations. You should explain what you can provide and what may be required from our side. For example: “I can provide samples, but I would need you to run the testing”.

2. General Information

a) Organisation/company/university name and address

b) The key contact person (including phone number and email address). 

Please send your proposal to open.innovation@emdgroup.com

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement